WAVE Life Sciences (NASDAQ:WVE – Get Free Report) and MannKind (NASDAQ:MNKD – Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, institutional ownership, dividends and risk.
Profitability
This table compares WAVE Life Sciences and MannKind’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| WAVE Life Sciences | -296.86% | -44.66% | -36.80% |
| MannKind | -11.08% | N/A | -6.31% |
Analyst Recommendations
This is a summary of recent ratings and recommmendations for WAVE Life Sciences and MannKind, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| WAVE Life Sciences | 1 | 2 | 15 | 2 | 2.90 |
| MannKind | 1 | 2 | 8 | 0 | 2.64 |
WAVE Life Sciences currently has a consensus price target of $20.89, indicating a potential upside of 481.86%. MannKind has a consensus price target of $8.08, indicating a potential upside of 130.95%. Given WAVE Life Sciences’ stronger consensus rating and higher probable upside, research analysts clearly believe WAVE Life Sciences is more favorable than MannKind.
Valuation & Earnings
This table compares WAVE Life Sciences and MannKind”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| WAVE Life Sciences | $42.73 million | 16.57 | -$204.38 million | ($1.07) | -3.36 |
| MannKind | $393.63 million | 2.86 | $5.86 million | ($0.13) | -26.92 |
MannKind has higher revenue and earnings than WAVE Life Sciences. MannKind is trading at a lower price-to-earnings ratio than WAVE Life Sciences, indicating that it is currently the more affordable of the two stocks.
Insider & Institutional Ownership
89.7% of WAVE Life Sciences shares are held by institutional investors. Comparatively, 49.5% of MannKind shares are held by institutional investors. 24.3% of WAVE Life Sciences shares are held by company insiders. Comparatively, 2.6% of MannKind shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Risk and Volatility
WAVE Life Sciences has a beta of -1.43, indicating that its stock price is 243% less volatile than the S&P 500. Comparatively, MannKind has a beta of 1.09, indicating that its stock price is 9% more volatile than the S&P 500.
Summary
WAVE Life Sciences beats MannKind on 8 of the 15 factors compared between the two stocks.
About WAVE Life Sciences
Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; siRNA clinical candidate for the treatment of obesity and other metabolic disorders; WVE-N531, a exon skipping oligonucleotide for the treatment of duchenne muscular dystrophy; and WVE-003, an antisense silencing oligonucleotide for the treatment of Huntington's disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was incorporated in 2012 and is based in Singapore.
About MannKind
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.
Receive News & Ratings for WAVE Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for WAVE Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
